Our pipeline is guided by our commitment to provide patients around the world with access to best-in-class living drugs, with faster treatment timelines, for a wide range of cancers
Our first IND is anticipated to be filed in 2019.
| Allogeneic format |
Invariant natural killer T cells (iNKT)
IND 2019 (Projected)
| Novel Targets |
Phosphopeptide Tumor Targets(PTTs)